BioSpace News Archive

Menarini Silicon Biosystems (MSB), Inc. is announcing that the AMA has issued Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) codes for two of its CELLSEARCH advanced liquid biopsy tests which received preliminary pricing determination by the US Centers for Medicare and Medicaid Services (CMS). Issuing of these codes represents a decisive step towards gaining broad access to Medicare/Medicaid reimbursement.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022 financial results and provide an update on the company’s business and outlook on Thursday, Oct. 27, at 4:30 p.m. ET.

Horizon Therapeutics plc to Present New Data on TEPEZZA ® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting.

Immuron Limited is pleased to announce that it has signed a strategic investment and option agreement with Ateria Health Limited, a U.K. based company that has developed ground-breaking product for the treatment of irritable bowel syndrome.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, and Visiopharm, a world leader in AI-driven digital pathology software, announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies.

Kineta, Inc. announced that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research Special Conference: Tumor Immunology and Immunotherapy, to be held on October 21-24, 2022 as an in-person event in Boston, Massachusetts.

ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today announced that Yuyuan Bioscience’s (Yuyuan) IND application for a Phase 1 clinical trial of nolasiban has been approved by the Center for Drug Evaluation at the Chinese National Medical Products Administration.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced acceptance for publication by Frontiers in Oncology of a case study using TransCode’s lead therapeutic candidate, TTX-MC138, in a feline patient with spontaneous metastatic breast cancer.

Pfizer Inc. and BioNTech SE announced early data from a Phase 2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

Samsung Biologics announced today it has successfully renewed its ISO 27001 certification (Information Security Management System) and obtained ISO 27017 certification (Information Security in cloud services) and ISO 37001 certification (Anti-bribery management systems).